The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Inception Date: 23/06/2005
Primary Benchmark: Dynamic Pharmaceutical Intellidex TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.57%
Management Expense Ratio: 0.56 %
|ABT||Abbott Laboratories||5.22 %|
|PFE||Pfizer Inc.||5.18 %|
|BIIB||Biogen Inc.||5.17 %|
|AMGN||Amgen Inc.||5.14 %|
|BMY||Bristol-Myers Squibb Company||5.12 %|
|LLY||Eli Lilly and Company||5.09 %|
|ABBV||AbbVie Inc.||5.03 %|
|CELG||Celgene Corporation||4.74 %|
|RTRX||Retrophin Inc.||3.12 %|
|VNDA||Vanda Pharmaceuticals Inc.||2.97 %|
|XLV||SPDR Select Sector Fund - Heal..||0.14 %||
|VHT||Vanguard Health Care||0.10 %||
|XBI||SPDR Series Trust S&P Biotech||0.35 %||
|IYH||iShares U.S. Healthcare||0.44 %||
|IHI||iShares U.S. Medical Devices||0.44 %||
|IXJ||iShares Global Healthcare||0.48 %||
|FBT||First Trust Amex Biotech Index..||0.56 %||
|FHLC||Fidelity MSCI Health Care Inde..||0.08 %||
|FXH||First Trust Health Care AlphaD..||0.62 %||
|HQH||Tekla Healthcare Investors||0.00 %||
|Market Performance vs.
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||21.34%||39%||F||33%||F|
|Risk Adjusted Return||50.18%||32%||F||47%||F|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.